On Thursday, Scotiabank adjusted its stock price target for Illumina (NASDAQ:ILMN), a leading developer of life science tools, reducing it to $164 from the previous $176. The firm maintained its Sector Outperform rating on the company's stock. This revision comes after Illumina hosted a Strategy Update call on Wednesday, where the company outlined its financial targets for the years 2025 to 2027.
During the call, Illumina projected an acceleration in revenue growth to high single digits by 2027, contrasting with a year-over-year decline of 2-3% in 2024. The company also anticipates a significant improvement in non-GAAP operating margins, with an expansion of over 500 basis points by 2027, up from the 20.5-21% range expected in 2024. This increase is partly attributed to an incremental cost savings of approximately $200 million.
Illumina expects to achieve double-digit to teens growth in non-GAAP earnings per share (EPS) annually. While these targets fall below Illumina's historical growth rates, the firm sees them as a solid foundation for the company and its new management to strive towards, especially given the current limited visibility in the life science tools industry's growth potential over the next 12 to 18 months.
Despite the reduction in the near-term revenue estimates and price target, Scotiabank remains optimistic about Illumina's long-term prospects. The bank cited the company's innovation pipeline and strong competitive position as reasons for potential top-line growth acceleration in the future.
It also referenced the overall serviceable addressable market for Illumina, which is expected to grow at a compound annual growth rate (CAGR) of approximately 12% over the next decade, rising from the current estimate of around $10 billion for both clinical and research applications.
In other recent news, Illumina Inc (NASDAQ:ILMN). has been a focal point of several significant developments. Following Illumina's recent GRAIL spinoff, TD Cowen upgraded the company's stock from Hold to Buy and raised the price target from $126 to $144. The firm believes that the spinoff simplifies Illumina's business narrative and allows the company to better focus on its core operations.
Stifel also reaffirmed its Buy rating on Illumina, maintaining a steady price target of $160.00. This decision followed Illumina's recent strategy day where the company outlined plans to enhance growth and profitability by launching new products within the next 12 to 18 months.
Illumina has also outlined a strategic vision aimed at accelerating revenue growth and expanding profit margins over the next three years. The company plans to innovate within its genomics portfolio and foster a new research partnership with the Broad Institute of MIT and Harvard to advance single-cell sequencing.
TD Cowen adjusted its outlook on Illumina after the company's mixed second-quarter results. Despite surpassing sales expectations, Illumina saw a decline in sequencing instruments revenue by 40% year-over-year. The company also completed the acquisition of Fluent (NASDAQ:FLNT) BioSciences, which is expected to enhance its multiomics capabilities and single-cell analysis technology.
Lastly, Illumina faced a challenging second quarter in 2024, marked by mixed financial results and strategic shifts. The company reported core revenue of $1.1 billion, with non-GAAP operating margins at 22.2%. Despite these challenges, Illumina remains focused on stabilizing its base and accelerating growth.
InvestingPro Insights
As Illumina (NASDAQ:ILMN) navigates a period of recalibrated expectations, real-time data from InvestingPro provides additional context for investors monitoring the company's performance. Illumina's revenue for the last twelve months as of Q2 2024 stands at $4.429 billion, with a slight year-over-year decline of 0.72%. Despite this, the company's gross profit margin remains robust at 66.34%, showcasing its ability to maintain profitability in core operations.
InvestingPro Tips suggest that while Illumina has not been profitable over the last twelve months, analysts are optimistic, forecasting a return to profitability this year. This aligns with the company's own projections of improved financial performance by 2027. Moreover, with 10 analysts having revised their earnings upwards for the upcoming period, there is a consensus of confidence in the company's potential to rebound. It's also worth noting that Illumina operates with a moderate level of debt, which may offer some financial flexibility as it pursues its strategic goals.
For investors seeking a deeper dive, there are additional InvestingPro Tips available, providing further analysis and guidance on Illumina's stock. While Illumina does not currently pay a dividend, suggesting a reinvestment of earnings into the company's growth, the long-term prospects highlighted by Scotiabank appear to be echoed by the insights from InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.